Trials / Recruiting
RecruitingNCT07221344
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 112 (estimated)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARO-MAPT-SC | • single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection |
| DRUG | Placebo | • calculated volume to match active treatment by SC administration |
Timeline
- Start date
- 2025-11-18
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2025-10-27
- Last updated
- 2026-04-15
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07221344. Inclusion in this directory is not an endorsement.